Making CME Matter®
Evolving Strategies in IBD: Targeting Learning to Close Gaps and Improve Outcomes
Gastroenterology
Curriculum:
Evolving Diagnostic and Treatment Strategies in Inflammatory Bowel Disease
Evolving Diagnostic and Treatment Strategies in Inflammatory Bowel Disease
Credits:
0.5 AAFP Prescribed Credit(s) 0.5 AANP Contact Hours 0.5 AMA PRA Category 1 Credit(s) ™
0.5 AAFP Prescribed Credit(s) 0.5 AANP Contact Hours 0.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
October 18, 2016
October 18, 2016
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Primary care physicians; gastroenterologists; nurse practitioners (NPs); physician assistants (PAs); and other clinicians.
Relevant Terms:
Inflammatory bowel disease; irritable bowel syndrome; abdominal pain; chronic diarrhea
Gerald W. Dryden, MD, PhD
Gerald W. Dryden, MD, PhD Professor of Medicine and Bioengineering Director, Clinical Trials Unit University of Louisville Louisville, KY
Bio
Dr. Gerald W. Dryden is a Professor of Medicine and Bioengineering and the Director of the Clinical Trials Unit at the University of Louisville. He joined the faculty of the University of Louisville after completing his residency, fellowship and obligated service with the US Navy. Dr. Dryden has been a practicing gastroenterologist for 17 years, and has had a focus in inflammatory bowel disease and GI immunology for the past 10 years. He also has a strong interest in innovation and improving clinical practice.
Dr. Dryden’s undergraduate degree, a Bachelor of Science in Agronomy, was earned from the University of Kentucky College of Agriculture. He then graduated from the University of Kentucky College of Medicine and began an eight-year period of active duty service with the US Navy. While in the Navy, he completed a residency in Internal Medicine and a fellowship in Gastroenterology. During his tenure at the University of Louisville, he received additional training, including a Master of Science in Public Health, a Master of Science in Microbiology and Immunology and a PhD in Microbiology and Immunology.
| 1. | Recognize the conditions referred to as inflammatory bowel disease (IBD), and evaluate the degree of severity based on clinical measures of disease activity | 2. | Match appropriate pharmacologic therapeutic strategies to clinical IBD presentations to maximize outcomes while minimizing toxicity |
| 3. | Identify patients who are at high risk of complications from IBD and who may benefit from new mechanisms of action in IBD therapy | 4. | Employ approaches to optimize benefits from IBD treatment options and facilitate adherence |
| 1. | Recognize the conditions referred to as inflammatory bowel disease (IBD), and evaluate the degree of severity based on clinical measures of disease activity |
| 2. | Match appropriate pharmacologic therapeutic strategies to clinical IBD presentations to maximize outcomes while minimizing toxicity |
| 3. | Identify patients who are at high risk of complications from IBD and who may benefit from new mechanisms of action in IBD therapy |
| 4. | Employ approaches to optimize benefits from IBD treatment options and facilitate adherence |
Planning Committee
Gregg Sherman, MD
Family Practice
Plantation, FL
Harvey C. Parker, Ph.D., CCMEP
National Association for Continuing Education
Plantation, FL
National Association for Continuing Education
Plantation, FL
Joshua Kilbridge, President
Kilbridge Associates
San Francisco, CA
Kilbridge Associates
San Francisco, CA
PROGRAM OVERVIEW:
Inflammatory bowel disease (IBD) is a term that encompasses chronic inflammatory disorders of the bowel, the most common of these being ulcerative colitis (UC) and Crohn's disease (CD). As many as 1.5 million persons in the United States may suffer from IBD accounting for over 700,000 physician visits, 100,000 hospitalizations, and disability in 119,000 patients every year in the United States. IBD is associated with an overall health care cost of more than $1.7 billion and adversely affects the quality of life of both patients and their families.
Inflammatory bowel disease (IBD) is a term that encompasses chronic inflammatory disorders of the bowel, the most common of these being ulcerative colitis (UC) and Crohn's disease (CD). As many as 1.5 million persons in the United States may suffer from IBD accounting for over 700,000 physician visits, 100,000 hospitalizations, and disability in 119,000 patients every year in the United States. IBD is associated with an overall health care cost of more than $1.7 billion and adversely affects the quality of life of both patients and their families.
Several diseases may mimic IBD clinically, and careful and repeated evaluations, as necessary, can reduce the likelihood of misdiagnosis. Even if clinical, radiographic, endoscopic, and histologic criteria are applied, the diagnosis of UC and CD is in doubt in 15% of the cases at initial presentation. In patients with UC having colectomy and ileal-pouch anal anastomosis, the diagnosis is subsequently changed to CD in 3% to 7% of the cases. Providing medical care for IBD patients can be complex, requiring strategies for inducing and maintaining disease remission as well as monitoring for intestinal and extraintestinal complications of the diseases and prescribed therapies. Standardized algorithms on care for IBD patients do not exist, resulting in variations in the quality of care, which include underuse, overuse, or misuse of medical services.
This program will help to bridge the knowledge and performance gaps related to identification, and management of Inflammatory Bowel Disease. This educational initiative offers a two-phased curriculum. Phase 1 will offer a Self Assessment Program (SAP) to allow learners to assess their knowledge and skills in this area, compare their selections and scores with all other learners to date, and review commentary from the faculty. The goal of the SAP is to make learners aware of their strengths and weaknesses in this subject area.
A second activity utilizing a case-based interactive structure will be developed in Phase 2 focused on these drivers. This two-phased approach incorporating these statistical techniques will not only provide the stakeholders of this curriculum with the guidance to create an activity that will have optimal impact on clinical behavior, but will significantly impact the development of future curricula as well.
DISCLOSURE POLICY STATEMENT:
It is the policy of NACE to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. NACE assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.
While NACE endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.
DISCLOSURE OF CONFLICTS OF INTEREST:
Faculty
Gerald W. Dryden, MD, MSPH, MSc, AGAF, FASGE, Course Director, has the follow to disclose: serves on the speaker’s bureaus of Abbvie, Takeda, EnteraHeatlh and Salix. Dr. Dryden also conducts contracted research for Abbvie, Johnson & Johnson, Merck, Takeda, Pfizer, and Genetech.
Planning Committee
Gregg Sherman, MD, has no real or apparent conflicts of interest to report.
Harvey Parker, PhD, has no real or apparent conflicts of interest to report.
Joshua Kilbridge has no real or apparent conflicts of interest to report.
DISCLOSURE OF UNLABELED USE:
NACE requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of NACE. The information is presented for the purpose of advancing the attendees' professional development.
For CME questions, please contact: NACE at info@naceonline.com.
Contact this CME provider for privacy and confidentiality policy statement information at: http://www.naceonline.com/privacy_policy.php.
ACCREDITATION STATEMENT:
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Association for Continuing Education designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This Enduring Material activity, Evolving Diagnostic and Treatment Strategies in Inflammatory Bowel Disease: Targeting Learning to Close Gaps and Improve Outcomes, has been reviewed and is acceptable for prescribed credit by the American Academy of Family Physicians. Term of approval begins 10/18/2016. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 0.5 contact hours of continuing education (which includes 0.25 hrs of pharmacology).
The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 0.5 contact hours of continuing education (which includes 0.25 hrs of pharmacology).
TO OBTAIN CME CREDITS:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
- You must score 60% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE FORMAT/MEDIUM: Internet CME Activity
ESTIMATED TIME TO COMPLETE: 30 minutes
ACKNOWLEDGEMENT:
This activity is sponsored by National Association for Continuing Education.
This educational activity is supported by an educational grant from Shire.
If you have any questions regarding this activity, send an email to info@naceonline.com.
Copyright © 2016 National Association for Continuing Education. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of NACE is prohibited.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2024 HealthCourse, Inc. All rights reserved.
